Bisacodyl: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Adeel Jamil (talk | contribs)
nocaptcha, Administrators
2,544 edits
No edit summary
Adeel Jamil (talk | contribs)
nocaptcha, Administrators
2,544 edits
No edit summary
Line 41: Line 41:




|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Bisacodyl in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Bisacodyl in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of Bisacodyl in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Bisacodyl in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Bisacodyl in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
Line 99: Line 99:




|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of Bisacodyl in the drug label.


=====Body as a Whole=====
=====Body as a Whole=====
Line 166: Line 166:


<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of Bisacodyl in the drug label.
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Bisacodyl in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=There is no FDA guidance on use of Bisacodyl during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInNursing=There is no FDA guidance on the use of Bisacodyl with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInPed=There is no FDA guidance on the use of Bisacodyl with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGeri=There is no FDA guidance on the use of Bisacodyl with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInGender=There is no FDA guidance on the use of Bisacodyl with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRace=There is no FDA guidance on the use of Bisacodyl with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInRenalImpair=There is no FDA guidance on the use of Bisacodyl in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInHepaticImpair=There is no FDA guidance on the use of Bisacodyl in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInReproPotential=There is no FDA guidance on the use of Bisacodyl in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
|useInImmunocomp=There is no FDA guidance one the use of Bisacodyl in patients who are immunocompromised.


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
Line 186: Line 186:


* Suppository  
* Suppository  
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of Bisacodyl in the drug label.




<!--IV Compatibility-->
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of Bisacodyl in the drug label.


<!--Overdosage-->
<!--Overdosage-->
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
|overdose=There is limited information regarding <i>Chronic Overdose</i> of Bisacodyl in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->
Line 252: Line 252:
|structure=*  
|structure=*  


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
: [[File:Bisacodyl01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of Bisacodyl in the drug label.


<!--Pharmacokinetics-->
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
|PK=There is limited information regarding <i>Pharmacokinetics</i> of Bisacodyl in the drug label.


<!--Nonclinical Toxicology-->
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of Bisacodyl in the drug label.


<!--Clinical Studies-->
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of Bisacodyl in the drug label.


<!--How Supplied-->
<!--How Supplied-->
Line 301: Line 301:
Bisacodyl USP LAXATIVE
Bisacodyl USP LAXATIVE
8 SUPPOSITORIES 10 mg each
8 SUPPOSITORIES 10 mg each
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of Bisacodyl in the drug label.


<!--Precautions with Alcohol-->
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-Bisacodyl interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


<!--Brand Names-->
<!--Brand Names-->
Line 313: Line 313:
}}
}}
{{LabelImage
{{LabelImage
|fileName={{PAGENAME}}11.png
|fileName=Bisacodyl11.png
}}
}}
{{LabelImage
{{LabelImage
|fileName={{PAGENAME}}11.png
|fileName=Bisacodyl11.png
}}
}}
<!--Pill Image-->
<!--Pill Image-->

Revision as of 20:34, 29 December 2014

Bisacodyl
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Adeel Jamil, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Bisacodyl is a laxatives that is FDA approved for the treatment of constipation. Common adverse reactions include nausea and vomiting..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Tablet Forms

for temporary relief of occasional constipation and irregularity this product generally produces a bowel movement in 6 to 12 hours

Dosing Information

take with a glass of water

table

Suppository Form

For the relief of occasional constipation. Bowel movement is generally produced in 15 minutes to 1 hour.

Dosing Information
see chart below for dose

• remove foil wrapper • insert suppository well up into the rectum as indicated, and retain it about 15 to 20 minutes

Table

• In the presence of anal fissures or hemorrhoids, suppositories should be coated at the tip with petroleum jelly.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Bisacodyl in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bisacodyl in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Bisacodyl in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Bisacodyl in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bisacodyl in pediatric patients.

Contraindications

There is limited information regarding Bisacodyl Contraindications in the drug label.

Warnings

Oral Form

Do not use 

if you cannot swallow without chewing.

Ask a doctor before use if you have stomach pain, nausea, or vomiting a sudden change in bowel habits that lasts more than 2 weeks When using this product do not chew or crush tablet(s) do not use within 1 hour after taking an antacid or milk it may cause stomach discomfort, faintness and cramps Stop use and ask a doctor if you have rectal bleeding or no bowel movement after using this product. These could be signs of a serious condition. you need to use a laxative for more than 1 week If pregnant or breast-feeding,

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Suppository Form

For rectal use only

Do not use laxative products for a period longer than one week unless directed by a doctor

Ask a doctor before use if you have • abdominal pain, nausea or vomiting • a sudden change in bowel habits that lasts longer than 2 weeks

Stop use and ask a doctor if rectal bleeding occurs or you fail to have a bowel movement after using a laxative. These may be signs of a serious condition.

KEEP OUT OF REACH OF CHILDREN If swallowed, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Bisacodyl in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Bisacodyl in the drug label.

Drug Interactions

There is limited information regarding Bisacodyl Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Bisacodyl in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Bisacodyl during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Bisacodyl with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Bisacodyl with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Bisacodyl with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Bisacodyl with respect to specific gender populations.

Race

There is no FDA guidance on the use of Bisacodyl with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Bisacodyl in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Bisacodyl in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Bisacodyl in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Bisacodyl in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Suppository

Monitoring

There is limited information regarding Monitoring of Bisacodyl in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Bisacodyl in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Bisacodyl in the drug label.

Pharmacology

Template:Px
Template:Px
Bisacodyl
Systematic (IUPAC) name
(pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate
OR
4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate
Identifiers
CAS number 603-50-9
ATC code A06AB02 A06AG02 (WHO)
PubChem 2391
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 361.391 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 15%
Metabolism Hepatic (CYP450-mediated)
Half life 16 Hours
Excretion primarily in the feces, systemically absorbed drug is excreted in the urine
Therapeutic considerations
Pregnancy cat.

C

Legal status

OTC

Routes Oral, rectal

Mechanism of Action

Bisacodyl works by stimulating enteric nerves to cause colonic mass movements (contractions). It is also a contact laxative; it increases fluid and NaCl secretion. Action of bisacodyl on small intestine is negligible; stimulant laxatives mainly promote evacuation of the colon

Structure

File:Bisacodyl01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Bisacodyl in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Bisacodyl in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Bisacodyl in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Bisacodyl in the drug label.

How Supplied

There is limited information regarding Bisacodyl How Supplied in the drug label.

Storage

store between 20º-25ºC (68º-77ºF)

Images

Drug Images

{{#ask: Page Name::Bisacodyl |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

Oral Form

Compare to the active ingredient in Dulcolax®*

Laxative

Bisacodyl

Stimulant laxative for gentle, dependable overnight relief Comfort Coated TABLETS 5 mg Each

  • This product is not manufactured or distributed by Boehringer Ingelheim Pharmaceuticals, Inc., distributor of Dulcolax® Laxative.

PROUDLY DISTRIBUTED BY:

VALU MERCHANDISERS, CO.

5000 KANSAS AVE

KANSAS CITY, KS 66106

TAMPER EVIDENT: DO NOT USE IF CARTON IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING.

KEEP OUTER CARTON FOR COMPLETE WARNINGS AND PRODUCT INFORMATION.


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL for Suppository NDC 0713-0109-08 G&W® BISAC-EVAC™ Bisacodyl USP LAXATIVE 8 SUPPOSITORIES 10 mg each {{#ask: Label Page::Bisacodyl |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Bisacodyl in the drug label.

Precautions with Alcohol

  • Alcohol-Bisacodyl interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Bisacodyl Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Bisacodyl Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject: 

 |Page Name=Bisacodyl
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Bisacodyl
 |Label Name=Bisacodyl11.png

}}

{{#subobject: 

 |Label Page=Bisacodyl
 |Label Name=Bisacodyl11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Bisacodyl&oldid=1051422"